HER2 overexpression is determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH), and is seen in about 20% of GC, which results in poor outcome and more aggressive disease course [11]. This evidence concerns the gene ERBB2 and gastric cancer.